Corona virus vaccine development in world and it's current status

Corona virus vaccine development in world and it's current status

In the race to develop a vaccine against the novel coronavirus, there are currently seven frontrunners, which are doing their best to find the vaccine, all of which some have entered human trials. Most countries around the world have seen cases of COVID-19 and many are experiencing outbreaks in very severe conditions. Authorities in China and some other countries have succeeded in showing their outbreaks.
In India, six firms are in various stages of pre-clinical vaccine development research, Experts estimate a novel coronavirus vaccine is around a year-and-a-half away but it might be for a generations.
In humanity’s fight against the novel coronavirus, vaccines have become the Holy Grail. The only way the threat posed by the current pandemic ends is if the human population develops immunity to the novel coronavirus. This immunity can either be acquired naturally, for which the virus will have to infect a large chunk of the global population or be induced with the help of worldwide vaccination programmes.
The novel coronavirus’s remarkable pace is matched by equally rapid advances made in science. It’s just been months since the novel coronavirus surfaced in humans, and scientists have already been able to launch projects to identify and develop vaccines to halt the virus’s through their worldwide march.
According to the World Health Organisation’s global database of research into the novel coronavirus, there are currently several vaccine candidates being tried on humans. We take a look at those prospects and give you a brief overview of the race to develop a novel coronavirus vaccine.
Before we delve in, a word about timelines: Vaccine research is a long process that usually involves at least three phases of clinical, or human, trials. The number of people being given an experimental vaccine increases at every stage with the ultimate goal of testing for safety, side-effects and, of course, the ability to induce immunity. This can take up to a decade.
However, the unprecedented nature of the current crisis has forced scientists to take ‘shortcuts’ while developing vaccines for the novel coronavirus. What this means is that the timelines mentioned in this article, which are based on the respective researchers’ own estimates, are optimistic and must be read with a pinch of salt.

Here are the vaccine name and how doctor’s are working their best to find the best.

AD5-NCOV – A joint effort by the Chinese biotech firm CanSino Biologics and an arm of the People’s Liberation Army, Ad5-nCoV was the first novel coronavirus vaccine to enter human trials. Ad5-nCoV is currently in Phase II clinical trials and is the farthest along in research for vaccines against the novel coronavirus.

CHADOX1- Developed by British scientists, ChAdOx1 is similar to the Chinese Ad5-nCoV in terms of the technique used to induce immunity. The shot is currently in combined Phase I/II clinical trials that aim to test the vaccine’s efficacy and safety.

INO-4800 – Developed by the US biotech firm Inovio Pharmaceuticals, INO-4800 is currently in Phase I clinical trials. INO-4800 has the backing of the Coalition for Epidemic Preparedness Innovations, a global vaccine research coalition founded by the governments of India and Norway, and the Bill and Melinda Gates Foundation, among others.

PICOVACC – Another Chinese candidate, PiCoVacc is an inactivated vaccine developed by the private biopharma company Sinovac. The vaccine, which is currently in combined Phase I/II trials, aims to generate an immune response by exposing the body to ‘inactivated’ cells of the novel corona other.

MRNA-1273 – Developed by the ten-year-old US biotech firm Moderna, mRNA-1273 is based on a radical – and so, largely untested – approach to vaccination that is similar in concept to a DNA vaccine such as the INO-4800.

BNT162 – Jointly developed by the German company BioNTech and US pharma giant Pfizer, BT162 is a group of four potential vaccines based on the messenger RNA, or mRNA, concept. The vaccines are about to be tested in combined Phase I/II trials in Germany and are likely to enter trials in the United States as well. The four vaccines use different mRNA technologies developed by BioNTech and more or less aim to get the body’s own cells to produce the novel coronavirus’s spike proteins. Just like with mRNA-1273, the technology used by these vaccines is radically new and so, remains largely untested.

Post a Comment